The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry.

The largest deal of the week was Genentech, Inc.‘s collaboration on pralsetinib with Blueprint Medicines Corporation valued at $775 million. Blueprint Medicines and Genentech will co-commercialize pralsetinib and equally share profits in the U.S. Roche will obtain an exclusive license to commercialize pralsetinib outside the U.S., excluding Greater China.

To subscribe to our Health Care M&A deals chart and more, visit our membership siteHealthCareMandA.com is devoted to healthcare merger and acquisition data for the serious analyst and investor. Every day, this service alerts you to developments in all the key segments of the health care service and technology markets.

Click here to view our quarterly and annual publications and here to view our monthly webinar series.

Biotechnology    
Acquirer Target Price
Genentech, Inc. Collaboration on pralsetinib $775,000,000
Kronos Bio, Inc. SYK inhibitor portfolio N/A
Home Health Care & Hospice    
Acquirer Target Price
Alleo Health System Upper Cumberland Hospice and Palliative Care Services N/A
Hospitals    
Acquirer Target Price
Banner Health Wyoming Medical Center $207,000,000
Cedars-Sinai Health System Huntington Hospital N/A
Laboratories, MRI and Dialysis    
Acquirer Target Price
Terumo Corporation Quirem Medical B.V. $20,000,000
Managed Care    
Acquirer Target Price
Molina Healthcare, Inc. Medicaid and DSNP assets $20,000,000
Medical Devices    
Acquirer Target Price
Medtronic plc Medicrea $158,744,198
Physician Medical Groups    
Acquirer Target Price
Pennsylvania Dermatology Partners 3 dermatology practices N/A
Other Services    
Acquirer Target Price
TriHealth TriHealth Surgery Center Anderson $21,000,000